Guidelines for immunizations in patients with inflammatory bowel disease

Bruce E. Sands, Carmelo Cuffari, Jeffry Katz, Subra Kugathasan, Jane Onken, Charles Vitek, Walter Orenstein

Research output: Contribution to journalArticle

Abstract

During the past 2 decades, medical therapy for Crohn's disease (CD) and ulcerative colitis (UC) has grown to incorporate a variety of immune-suppressing agents. At the same time, basic insights into the aberrant mucosal immune response underlying inflammatory bowel disease (IBD) have expanded dramatically. The interplay of host susceptibility to infection and the safety and efficacy of immunization for vaccine-preventable diseases has been explored in other immune-mediated disease states but only rarely in IBD. The purpose of this review is to formulate best-practice recommendations for immunization in children and adults with IBD by considering the effects of the IBD disease state and its treatments on both the safety and efficacy of immunization. To do so, we first considered the routine recommendations for immunization of children, adults and distinct populations at increased risk for vaccine-preventable disease. Because it was rarely possible to examine direct data on safety and efficacy of immunization in IBD populations, we relied to a large extent upon extrapolation from similar populations and from knowledge of basic mechanisms. The literature suggests that efficacy of immunization may be diminished in some patients whose immune status is compromised by immune suppression. However, except for live agent vaccines, most immunizations may be safely administered to patients with IBD even when immune compromised. Conversely, protection against vaccine-preventable illness may be of even greater benefit to those at risk for morbid or lethal complications of infections because of an immune compromised state. We conclude that for most patients with IBD, recommendations for immunization do not deviate from recommended schedules for the general population.

Original languageEnglish (US)
Pages (from-to)677-692
Number of pages16
JournalInflammatory Bowel Diseases
Volume10
Issue number5
DOIs
StatePublished - Sep 2004

Fingerprint

Inflammatory Bowel Diseases
Immunization
Guidelines
Vaccines
Safety
Population
Mucosal Immunity
Immune System Diseases
Infection
Ulcerative Colitis
Practice Guidelines
Crohn Disease
Appointments and Schedules
Therapeutics

Keywords

  • Crohn's disease
  • Immune suppression
  • Immunization
  • Inflammatory bowel disease
  • Ulcerative colitis
  • Vaccination

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Guidelines for immunizations in patients with inflammatory bowel disease. / Sands, Bruce E.; Cuffari, Carmelo; Katz, Jeffry; Kugathasan, Subra; Onken, Jane; Vitek, Charles; Orenstein, Walter.

In: Inflammatory Bowel Diseases, Vol. 10, No. 5, 09.2004, p. 677-692.

Research output: Contribution to journalArticle

Sands, BE, Cuffari, C, Katz, J, Kugathasan, S, Onken, J, Vitek, C & Orenstein, W 2004, 'Guidelines for immunizations in patients with inflammatory bowel disease', Inflammatory Bowel Diseases, vol. 10, no. 5, pp. 677-692. https://doi.org/10.1097/00054725-200409000-00028
Sands, Bruce E. ; Cuffari, Carmelo ; Katz, Jeffry ; Kugathasan, Subra ; Onken, Jane ; Vitek, Charles ; Orenstein, Walter. / Guidelines for immunizations in patients with inflammatory bowel disease. In: Inflammatory Bowel Diseases. 2004 ; Vol. 10, No. 5. pp. 677-692.
@article{ebed827bbcf4417e8bc78af4dc104375,
title = "Guidelines for immunizations in patients with inflammatory bowel disease",
abstract = "During the past 2 decades, medical therapy for Crohn's disease (CD) and ulcerative colitis (UC) has grown to incorporate a variety of immune-suppressing agents. At the same time, basic insights into the aberrant mucosal immune response underlying inflammatory bowel disease (IBD) have expanded dramatically. The interplay of host susceptibility to infection and the safety and efficacy of immunization for vaccine-preventable diseases has been explored in other immune-mediated disease states but only rarely in IBD. The purpose of this review is to formulate best-practice recommendations for immunization in children and adults with IBD by considering the effects of the IBD disease state and its treatments on both the safety and efficacy of immunization. To do so, we first considered the routine recommendations for immunization of children, adults and distinct populations at increased risk for vaccine-preventable disease. Because it was rarely possible to examine direct data on safety and efficacy of immunization in IBD populations, we relied to a large extent upon extrapolation from similar populations and from knowledge of basic mechanisms. The literature suggests that efficacy of immunization may be diminished in some patients whose immune status is compromised by immune suppression. However, except for live agent vaccines, most immunizations may be safely administered to patients with IBD even when immune compromised. Conversely, protection against vaccine-preventable illness may be of even greater benefit to those at risk for morbid or lethal complications of infections because of an immune compromised state. We conclude that for most patients with IBD, recommendations for immunization do not deviate from recommended schedules for the general population.",
keywords = "Crohn's disease, Immune suppression, Immunization, Inflammatory bowel disease, Ulcerative colitis, Vaccination",
author = "Sands, {Bruce E.} and Carmelo Cuffari and Jeffry Katz and Subra Kugathasan and Jane Onken and Charles Vitek and Walter Orenstein",
year = "2004",
month = "9",
doi = "10.1097/00054725-200409000-00028",
language = "English (US)",
volume = "10",
pages = "677--692",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Guidelines for immunizations in patients with inflammatory bowel disease

AU - Sands, Bruce E.

AU - Cuffari, Carmelo

AU - Katz, Jeffry

AU - Kugathasan, Subra

AU - Onken, Jane

AU - Vitek, Charles

AU - Orenstein, Walter

PY - 2004/9

Y1 - 2004/9

N2 - During the past 2 decades, medical therapy for Crohn's disease (CD) and ulcerative colitis (UC) has grown to incorporate a variety of immune-suppressing agents. At the same time, basic insights into the aberrant mucosal immune response underlying inflammatory bowel disease (IBD) have expanded dramatically. The interplay of host susceptibility to infection and the safety and efficacy of immunization for vaccine-preventable diseases has been explored in other immune-mediated disease states but only rarely in IBD. The purpose of this review is to formulate best-practice recommendations for immunization in children and adults with IBD by considering the effects of the IBD disease state and its treatments on both the safety and efficacy of immunization. To do so, we first considered the routine recommendations for immunization of children, adults and distinct populations at increased risk for vaccine-preventable disease. Because it was rarely possible to examine direct data on safety and efficacy of immunization in IBD populations, we relied to a large extent upon extrapolation from similar populations and from knowledge of basic mechanisms. The literature suggests that efficacy of immunization may be diminished in some patients whose immune status is compromised by immune suppression. However, except for live agent vaccines, most immunizations may be safely administered to patients with IBD even when immune compromised. Conversely, protection against vaccine-preventable illness may be of even greater benefit to those at risk for morbid or lethal complications of infections because of an immune compromised state. We conclude that for most patients with IBD, recommendations for immunization do not deviate from recommended schedules for the general population.

AB - During the past 2 decades, medical therapy for Crohn's disease (CD) and ulcerative colitis (UC) has grown to incorporate a variety of immune-suppressing agents. At the same time, basic insights into the aberrant mucosal immune response underlying inflammatory bowel disease (IBD) have expanded dramatically. The interplay of host susceptibility to infection and the safety and efficacy of immunization for vaccine-preventable diseases has been explored in other immune-mediated disease states but only rarely in IBD. The purpose of this review is to formulate best-practice recommendations for immunization in children and adults with IBD by considering the effects of the IBD disease state and its treatments on both the safety and efficacy of immunization. To do so, we first considered the routine recommendations for immunization of children, adults and distinct populations at increased risk for vaccine-preventable disease. Because it was rarely possible to examine direct data on safety and efficacy of immunization in IBD populations, we relied to a large extent upon extrapolation from similar populations and from knowledge of basic mechanisms. The literature suggests that efficacy of immunization may be diminished in some patients whose immune status is compromised by immune suppression. However, except for live agent vaccines, most immunizations may be safely administered to patients with IBD even when immune compromised. Conversely, protection against vaccine-preventable illness may be of even greater benefit to those at risk for morbid or lethal complications of infections because of an immune compromised state. We conclude that for most patients with IBD, recommendations for immunization do not deviate from recommended schedules for the general population.

KW - Crohn's disease

KW - Immune suppression

KW - Immunization

KW - Inflammatory bowel disease

KW - Ulcerative colitis

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=4644359971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644359971&partnerID=8YFLogxK

U2 - 10.1097/00054725-200409000-00028

DO - 10.1097/00054725-200409000-00028

M3 - Article

C2 - 15472534

AN - SCOPUS:4644359971

VL - 10

SP - 677

EP - 692

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 5

ER -